In 1982, in response to growing evidence of resistance to the antibacterial drug, dapsone, WHO recommended that all patients with leprosy be treated with a short-course combination of three antibacterial drugs, rifampicin, dapsone, and clofazimine.1 This multidrug therapy reduced the number of patients with leprosy being treated from 5·3 million in 1985 to 3·1 million in 1991.2 The reduction in prevalence inspired the World Health Assembly in 1991 to set a target to eliminate leprosy as a public health problem by 2000, defining elimination as a global prevalence rate below one case per 10 000 of the population.
BT - The Lancet. Infectious diseases C1 -
http://www.ncbi.nlm.nih.gov/pubmed/27036335
DO - 10.1016/S1473-3099(16)00087-6 IS - 4 J2 - The Lancet Infectious Diseases N2 -
In 1982, in response to growing evidence of resistance to the antibacterial drug, dapsone, WHO recommended that all patients with leprosy be treated with a short-course combination of three antibacterial drugs, rifampicin, dapsone, and clofazimine.1 This multidrug therapy reduced the number of patients with leprosy being treated from 5·3 million in 1985 to 3·1 million in 1991.2 The reduction in prevalence inspired the World Health Assembly in 1991 to set a target to eliminate leprosy as a public health problem by 2000, defining elimination as a global prevalence rate below one case per 10 000 of the population.
PY - 2016 T2 - The Lancet. Infectious diseases TI - Time to define leprosy elimination as zero leprosy transmission? UR - http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)00087-6/fulltext VL - 16 SN - 14733099 ER -